Escitalopram is not a controlled substance in the United Kingdom, so you may travel with a prescription label or a doctor’s note. Keep the medication in its original container and declare it if required by the destination country’s customs regulations.
Escitalopram is not listed as a prohibited substance by major sports anti-doping agencies. However, disclose any medication use to the testing authority if you are subject to a therapeutic use exemption.
In the UK, 5 mg tablets are typically white, 10 mg tablets are pink, and 20 mg tablets are orange, each bearing the imprint “ESC 5”, “ESC 10”, or “ESC 20” respectively. Inactive ingredients may include lactose, magnesium stearate, and microcrystalline cellulose.
All approved brands contain the same escitalopram anhydrous molecule and must meet MHRA bioequivalence standards. Differences may lie in tablet colour, shape, or inactive excipients, which can affect tolerability for patients with allergies (e.g., lactose intolerance).
Clinical benefits often begin within 2 weeks, but full therapeutic effect may take 4-6 weeks. Patience and adherence are essential; discuss any concerns with your prescriber before altering the dose.
Some antihistamine sleep aids (e.g., diphenhydramine) can increase sedation when combined with escitalopram. Consult a pharmacist to choose a non-sedating alternative, such as melatonin, if needed.
Escitalopram crosses the placenta and is classified as a Category C medication in the UK. It may be continued if the benefits outweigh potential risks, but neonates can experience adaptation syndrome (e.g., respiratory distress, jitteriness). Discuss the risk-benefit balance with your obstetrician.
Take the missed tablet as soon as you remember, unless it is close to the time of your next scheduled dose. Do not double the dose; simply continue with your regular once-daily schedule.
Weight changes are possible but not universal. Some patients report slight weight loss initially due to reduced appetite, while others may gain weight over long-term use. Monitor your weight and discuss any concerns with your clinician.
Both are SSRIs with similar efficacy for generalized anxiety disorder. Escitalopram has a slightly more favorable side-effect profile in some studies (e.g., lower rates of gastrointestinal upset), but individual response varies. Your prescriber will select the agent best suited to your clinical picture.
Escitalopram is an antidepressant medication belonging to the class of selective serotonin reuptake inhibitors (SSRIs). It is available in pill form in strengths of 5 mg, 10 mg, and 20 mg. In the United Kingdom, escitalopram is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is marketed under several brand names, but the active component is the same escitalopram molecule.
Escitalopram increases the level of the neurotransmitter serotonin in the brain by selectively inhibiting its re-uptake into neurons. Higher serotonin activity improves mood, anxiety, and certain pain pathways. The drug reaches peak plasma concentrations about 4-6 hours after oral ingestion, and its effects on serotonin re-uptake persist for the duration of the dosing interval. Escitalopram is metabolised primarily by the liver enzyme CYP2C19 (with minor contributions from CYP3A4 and CYP2D6) and has an elimination half-life of roughly 27-32 hours, allowing once-daily dosing.
Escitalopram is approved by the MHRA for the following adult indications:
These are the primary therapeutic uses; clinicians may select escitalopram based on individual response, tolerability, and co-existing conditions.
Some peer-reviewed studies have examined escitalopram for conditions that are not formally approved in the UK:
Off-label use is not approved by regulatory agencies and requires careful medical supervision and individualized risk assessment.
Ideal candidates are adults with a confirmed diagnosis of depression or anxiety who have no contraindicating medical conditions and are not taking interacting serotonergic agents.
Standard dosing:
Adults usually start with 10 mg once daily.
If needed, the dose may be increased after at least one week to 20 mg once daily.
The maximum recommended dose is 20 mg per day.
Special populations:
Elderly or patients with hepatic impairment - begin with 5 mg daily; titrate slowly.
Renal impairment - no formal dose reduction, but monitor for adverse effects.
Administration:
Swallow the pill whole with water; can be taken with or without food.
Store tablets at room temperature, away from moisture and heat.
Missed dose: Take the missed tablet as soon as you remember unless it is close to the time of the next scheduled dose. Do not double the dose.
Overdose: Symptoms may include nausea, vomiting, tremor, drowsiness, and seizures. Seek emergency medical care; supportive care is the mainstay of treatment.
Discontinuation: Do not stop abruptly. Gradual tapering over 2-4 weeks reduces the risk of discontinuation syndrome (e.g., electric-shock sensations, irritability).
This article provides educational information about escitalopram and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
